APOE and early-onset autosomal dominant Alzheimer disease: A clinical trial using this approach is currently in phase I (NCT03634007: ‘Gene Therapy for APOE4 Homozygote of Alzheimer’s Disease’), aiming to assess the safety and toxicity of intracisternal administration of AAVrh.